Psychedelic medicine has crossed from counterculture to regulatory endgame. Compass Pathways (CMPS) has now hit the primary endpoint in two separate Phase 3 trials of COMP360 psilocybin for treatment-resistant depression, with a New Drug Application targeted for the fourth quarter of 2026. If accepted and approved, it would be the first classic psychedelic ever cleared by the FDA. The second act is already queued: Definium Therapeutics (DFTX), the company formerly known as MindMed, reads out two Phase 3 LSD-derived programs in the second half of 2026, AtaiBeckley (ATAI) is moving its Breakthrough-designated mebufotenin nasal spray into Phase 3, and the FDA finalized its psychedelic trial guidance in July 2026, replacing ambiguity with a rulebook. The MDMA application rejected in 2024 was resubmitted for PTSD this week under new ownership. Commercial proof is no longer hypothetical: Johnson and Johnson (JNJ) runs Spravato, the ketamine-derived nasal spray, at a run rate near two billion dollars a year through more than 7,000 certified clinics, the exact infrastructure a psilocybin label would inherit. Big pharma has begun paying for optionality, led by AbbVie (ABBV) and its acquisition of a short-acting psychedelic for depression in a deal worth up to 1.2 billion dollars. The unresolved risk sits in the services layer: state-legal psilocybin centers in Oregon and Colorado run on cash-pay economics of 1,000 to 5,000 dollars per session with essentially no insurance coverage, a model that likely consolidates hard before reimbursement arrives. Five trends follow: the approval endgame, the readout wave, the clinic rails, the pharma option book, and the services shakeout. Risk-forward throughout: binary trial outcomes dominate this theme.
Compass Pathways (CMPS) achieved the primary endpoint in both pivotal COMP360 trials, COMP005 against placebo and COMP006 across two fixed doses, in treatment-resistant depression. The field it would validate is close behind: AtaiBeckley (ATAI), formed when atai Life Sciences absorbed Beckley Psytech in November 2025, is advancing its Breakthrough-designated BPL-003 mebufotenin nasal spray toward Phase 3, and GH Research (GHRS) is developing an inhaled mebufotenin candidate for the same indication. The January 2026 rebrand wave, MindMed becoming Definium and Cybin becoming Helus Pharma (HELP), reads as a sector dressing for institutional ownership rather than novelty. An approval would force scheduling review, REMS design, and payer policy conversations all at once.
COMP006 delivered a 3.8 point placebo-adjusted improvement on the MADRS depression scale at week 6 with p<0.001 across two fixed doses; COMP005 hit its primary endpoint with a single 25 mg dose in 258 participants across 32 US sites. The NDA submission is targeted for the fourth quarter of 2026, with 26-week durability data from COMP006 due in the same window, and an FDA decision widely expected in late 2026 or 2027.
The endgame question is no longer whether psilocybin can win a trial; it is whether a filing, a schedule, and a price can be agreed inside 18 months. Size positions to survive a binary regulatory outcome.
Definium Therapeutics (DFTX), formerly MindMed, reads out the Panorama study in generalized anxiety and Part A of the Emerge study in major depression in the second half of 2026, both for DT120, an LSD-derived orally disintegrating tablet holding FDA Breakthrough Therapy Designation. Helus Pharma (HELP), formerly Cybin, is deep into the APPROACH pivotal for its deuterated psilocin candidate, and the resubmitted MDMA application for PTSD now sits with the FDA under its new sponsor, Resilient Pharmaceuticals. The picks-and-shovels layer is quieter but real: IQVIA (IQV) and Charles River (CRL) run and support these trials, while Thermo Fisher (TMO) anchors the GMP manufacturing chain that scheduled substances require. The FDA's July 2026 final guidance standardized psychedelic trial design, which raises the cost of entry and rewards incumbents already built for it.
Definium's Phase 2b showed a 65% clinical response rate and 48% remission at 12 weeks in generalized anxiety. Two anxiety pivotals and one depression pivotal read out by early 2027, and the resubmitted MDMA NDA advances without a new Phase 3 behind it. Binary dispersion is extreme in this cohort: single-readout moves of 50% or more in either direction are within the historical range.
Treat the wave as a calendar of coin flips with asymmetric information value: every readout, pass or fail, tightens the regulatory map for the programs behind it.
Johnson and Johnson (JNJ) grew Spravato 46% year over year to 468 million dollars in the first quarter of 2026, delivered through more than 7,000 REMS-certified treatment sites, up from 2,800 in 2024. That certified lattice of monitored dosing rooms, trained staff, and established billing codes is the infrastructure a psilocybin or LSD label would rent on day one. The behavioral-health delivery layer beneath it is publicly investable: Acadia Healthcare (ACHC) in dedicated facilities, Universal Health Services (UHS) in hospital psychiatry, LifeStance Health (LFST) in outpatient networks, and Teladoc Health (TDOC) in telepsychiatry wrap the patient funnel from screening to follow-up.
Spravato passed a 1.9 billion dollar annualized run rate in the first quarter of 2026, with consensus near 2.3 billion dollars for the full year and sell-side peak estimates as high as 5 billion. More than 200,000 patients have been treated to date, up from 140,000 at the start of 2025. Monotherapy approval in January 2025 removed the oral-antidepressant tether, and certified sites grew roughly 2.5x in two years.
Own the rails, not just the trains: whichever molecules win approval will pay whoever already holds certified rooms and psychiatric throughput.
AbbVie (ABBV) acquired bretisilocin, a short-acting serotonin 2A agonist for major depressive disorder, from Gilgamesh Pharmaceuticals in August 2025 for up to 1.2 billion dollars, layered on top of the discovery alliance the two signed in 2024 worth up to 1.95 billion. Bristol Myers Squibb (BMY) paid 14 billion dollars for Karuna to enter next-generation neuropsychiatry with Cobenfy, and CNS specialists Neurocrine Biosciences (NBIX), Jazz Pharmaceuticals (JAZZ), and Supernus Pharmaceuticals (SUPN) form the acquirer bench behind them. The design goal across the second generation is a shorter, cheaper treatment session: bretisilocin's brief psychoactive window, versus six-plus hours for psilocybin, is the difference between a boutique protocol and an insurable one.
Cobenfy booked 63 million dollars in the second quarter of 2026, up 81% year over year, in its first full launch year after the 14 billion dollar Karuna acquisition. Bretisilocin cleared Phase 2a with a statistically significant reduction on the MADRS depression scale against a low-dose active comparator and is advancing toward Phase 3 under AbbVie. Spravato's near 2 billion dollar run rate is the revenue template these checks are underwriting.
The signal is the check size: strategics are underwriting the second generation before the first is even approved, which caps the worst-case narrative for the whole field.
Oregon and Colorado now operate regulated psilocybin programs, and a 2026 access report counts 241 verified psychedelic providers across 21 states including ketamine clinics, but the unit economics are unforgiving: facilitator hours, monitored sessions, and federal Schedule I status keep costs high while insurers sit out. Colorado law explicitly does not require coverage of natural medicine services, and only a single Oregon center has managed even partial insurance acceptance. The public-market read-through runs through the payers who will eventually set reimbursement, UnitedHealth Group (UNH) and The Cigna Group (CI), through the cash-pay telehealth model of Hims and Hers Health (HIMS) that clinics increasingly imitate, and through medical-outpatient landlords like Healthpeak Properties (DOC) that lease to behavioral tenants.
Psilocybin sessions price at 1,000 to 5,000 dollars in Oregon and 1,500 to 3,500 dollars in Colorado; ketamine infusion series run 2,400 to 6,400 dollars out of pocket. Federal Schedule I status blocks standard billing entirely. An FDA approval of COMP360, with a decision widely expected in late 2026 or 2027, is the most likely trigger for rescheduling and first coverage policies, which leaves a multi-year cash-pay gap between legality and reimbursement.
The bearish call is on the interim business model, not the therapy: survivors of the cash-pay winter will be worth owning, but the winter comes first.
This briefing is one run. Generate live macro intelligence across any sector, on demand, free.
🚀 Enter Just Signal